-
1Academic Journal
Συγγραφείς: Sharykin, A.S., Badtieva, V.A., Pavlov, V.I., Ivanova, Yu.M., Usmanov, D.M.
Θεματικοί όροι: A. Pelliccia classification, heart remodeling, гипертрофия миокарда левого желудочка, athletes, VO2 Peak, ремоделирование сердца, УДК 796.012.432.2, классификация A. Pelliccia, left ventricular myocardial hypertrophy, спортсмены, пиковое потребление кислорода
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://dspace.susu.ru/xmlui/handle/00001.74/62447
-
2Academic Journal
Συγγραφείς: Sheveleva, M. I., Trunova, Y. A., Шевелева, М. И., Трунова, Ю. А.
Πηγή: Сборник статей
Θεματικοί όροι: ARTERIAL HYPERTENSION, LEFT VENTRICULAR MYOCARDIAL HYPERTROPHY, SPORTS HEART STRAIN SYNDROME, CHILDREN, ГИПЕРТРОФИЯ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА, АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ, «СПОРТИВНОЕ СЕРДЦЕ», ДЕТИ
Περιγραφή αρχείου: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/10111
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/10111
-
3Academic Journal
Συνεισφορές: Малах, О. Н., науч. рук.
Θεματικοί όροι: гипертрофия миокарда левого желудочка, конькобежцы, ремоделирование сердца, спортивная медицина, сердце, спортивная квалификация, эхокардиография
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://rep.vsu.by/handle/123456789/34772
-
4Academic Journal
Συνεισφορές: Малах, О. Н., науч. рук.
Θεματικοί όροι: гипертрофия миокарда левого желудочка, тяжелоатлеты, спортивная медицина, электрокардиография (ЭКГ), морфометрия, сердце, спортивная квалификация
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://rep.vsu.by/handle/123456789/34773
-
5Academic Journal
Συγγραφείς: Sharykin, A.S., Badtieva, V.A., Pavlov, V.I., Ivanova, Yu.M., Usmanov, D.M.
Θεματικοί όροι: A. Pelliccia classification, heart remodeling, гипертрофия миокарда левого желудочка, athletes, VO2 Peak, УДК 616, ремоделирование сердца, 616 [УДК 796.01], классификация Pelliccia A, left ventricular myocardial hypertrophy, спортсмены, пиковое потребление кислорода
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://dspace.susu.ru/xmlui/handle/00001.74/51414
-
6Academic Journal
Θεματικοί όροι: гипертрофия миокарда левого желудочка, направленность тренировочного процесса, ремоделирование сердца, дилатация, спортивная квалификация, геометрия сердца, спортсмены-конькобежцы
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://rep.vsu.by/handle/123456789/30567
-
7Academic Journal
Θεματικοί όροι: гипертрофия миокарда левого желудочка, эхокардиографические показатели, тренировочный процесс, спортсмены-конькобежцы
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://rep.vsu.by/handle/123456789/29959
-
8Academic Journal
Συγγραφείς: M. A. Popov, D. V. Shumakov, D. I. Zybin, E. G. Agafonov, М. А. Попов, Д. В. Шумаков, Д. И. Зыбин, Е. Г. Агафонов
Συνεισφορές: The study was performed without external funding., Исследование проводилось без спонсорской поддержки.
Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 12, № 1 (2020); 42-48 ; Трансплантология; Том 12, № 1 (2020); 42-48 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2020-12-1
Θεματικοί όροι: терминальная сердечная недостаточность, left ventricular myocardial hypertrophy, expanded criteria organs, expanded criteria donor, terminal heart failure, гипертрофия миокарда левого желудочка, органы с расширенными критериями использования, доноры с расширенными критериями
Περιγραφή αρχείου: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/478/548; https://www.jtransplantologiya.ru/jour/article/view/478/555; Messerley FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603. PMID: 17707755 https://doi.org/10.1016/s0140-6736(07)61299-9; Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension. 2007;49(6):1385– 1391. PMID: 17404181 https://doi.org/10.1161/hypertensionaha.107.087890; Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli VP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. PMID: 2139921 https://doi.org/10.1056/nejm199005313222203; Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352. PMID: 1825164 https://doi.org/10.7326/0003-4819-114- 5-345; Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendation for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108. PMID: 16458610 https://doi.org/10.1016/j.euje.2005.12.014; Russo MJ, Davies RR, Hong KN, Chen JM, Argenziano M, Moskowitz A, et al. Matching high-risk recipients with marginal donor hearts is a clinically effective strategy. Ann Thorac Surg. 2009;87(4):1066–1070. PMID: 19324129 https://doi.org/10.1016/j. athoracsur.2008.12.020; Wever PO, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant. 2011;11(12):2755– 2761. PMID: 21906259 https://doi.org/10.1111/j.1600-6143.2011.03744.x; Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail. 2013;6(2):300–309. PMID: 23392789 https://doi.org/10.1161/circheartfailure.112.000165; Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. J Am Coll Cardiol. 2012;60(3):235– 236. PMID: 22789890 https://doi.org/10.1016/j.jacc.2012.04.016; Venkateswaran RV, Townend JN, Wilson IC, Mascaro JG, Bonser RS, Steeds RP. Echocardiography in the potential heart donor. Transplantation. 2010;89(7):894–901. PMID: 20075789 https://doi.org/10.1097/tp.0b013e3181cfe8e9; Zaroff JG, Babcock WD, Shi boski SC, Solinger LL, Rosengard BR. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. J Heart Lung Transplant. 2003;22(4):383–388. PMID: 12681416 https://doi.org/10.1016/s1053-2498(02)00561-2; Chen CW, Sprys MH, Gaffey AC, Chung JJ, Margulies KB, Acker MA, et al. The low ejection fraction in donor hearts is not directly related to increase recipient mortality. J Heart Lung Transplant. 2017;36(6):611– 615. PMID: 28314504 https://doi.org/10.1016/j.healun.2017.02.001; Marelli D, Laks H, Fazio D, Moore S, Moriguchi J,Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000;19(5):496–503. PMID: 10808159 https://doi.org/10.1016/s1053-2498(00)00076-0; Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM, et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997;10(6):446–450. PMID: 9428118 https://doi.org/10.1007/s001470050084; Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008;51(12):1214– 1220. PMID: 18355661 https://doi.org/10.1016/j.jacc.2007.11.052; Kittleson M, Patel J, Chang DH, Kransdorf E, Levine R, Dimbil S, et al. Donor left ventricular hypertrophy: over-rated or does donor history of hypertension make a difference for post-heart transplant outcome? J Heart Lung Transplantation. 2019;38(4 Suppl):S269. https://doi.org/10.1016/j. healun.2019.01.670; Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbacher DG, et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-. Circulation. 2001;104(6):676–681. https://doi.org/10.1161/hc3101.093765; Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor- provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–1252. PMID: 9054856 https://doi.org/10.1161/01.cir.95.5.1247; McKoy RC, Uretsky BF, Kormos R, Hardesty RL, Griffith BP, Salerni R, et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62(4):1140– 1142. PMID: 2973223 https://doi.org/10.1016/0002-9149(88)90570-x; Ventura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8(4):233–237. PMID: 8021902; Calò L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transplant Int. 2000;13(Suppl 1):413–418. PMID: 11112045 https://doi.org/10.1007/s001470050374; Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporine-Induced Hypertension: incidence, pathogenesis and management. Drug Safety. 1999;20(5):437–449. PMID: 10348094 https://doi.org/10.2165/00002018- 199920050-00004; Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B, Uber W, et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(2):145– 151. PMID: 17258148 https://doi.org/10.1016/j.healun.2006.11.003; Morgan JA, John R, Weinberg AD, Remoli R, Kherani AR, Vigilance DW, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg. 2003;76(6):1982–1987. PMID: 14667625 https://doi.org/10.1016/s0003-4975(03)01070-1; Everett JE, Djalilian AR, Kubo SH, Kroshus TJ, Shumway SJ. Heart transplantation for patients over age 60. Clin Transplant. 1996;10(6Pt1):478–81. PMID: 8996766; Blanche C, Blanche DA, Kearney B, Sandhu M, Czer LS, Kamlot A, et al. Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg. 2001;121(3):532–541. PMID: 11241089 https://doi.org/10.1067/mtc.2001.112831; Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443– 447. PMID: 12123210 https://doi.org/10.1034/j.1600-6143.2002.20508.x; Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg. 2003;125(1):49–59. PMID: 12538985 https://doi.org/10.1067/mtc.2003.62; Laks H, Marelli D. The alternate recipient list for heart transplantation: a model for expansion of the donor pool. Adv Card Surg. 1999;11:233–244. PMID: 10575495; Шевченко А.О., Фараджов Р.А., Изотов Д.А., Колоскова Н.Н., Никитина Е.А., Гичкун О.Е. и др. Ингибиторы ангиотензинпревращающего фермента у реципиентов сердца: результаты одноцентрового исследования. Вестник трансплантологии и искусственных органов. 2018;20(4):14–21.; Попцов В.Н., СпиринаЕ.А., Устин С.Ю., Масютин С.А., Догонашева А.А., Воронков В.Ю. и др. Трансплантация донорского сердца с гипертрофией миокарда левого желудочка 1,5 см и более. Вестник трансплантологии и искусственных органов. 2019;21(1):7–16.; https://www.jtransplantologiya.ru/jour/article/view/478
-
9Academic Journal
Συγγραφείς: M. P. Vasilyeva, I. M. Kutyrina, I. E. Rudenko, N. I. Solomakhina
Πηγή: Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 30, Pp 12-17 (2016)
Θεματικοί όροι: гипертрофия миокарда левого желудочка, 03 medical and health sciences, 0302 clinical medicine, хроническая болезнь почек, pulmonary hypertension, легочная гипертензия, Medicine, chronic kidney disease, left ventricular hypertrophy
Σύνδεσμος πρόσβασης: https://www.almclinmed.ru/jour/article/download/283/289
https://doaj.org/article/111b63b8ac26488dbc4ae4ae72d11714
https://cyberleninka.ru/article/n/otsenka-legochnoy-gipertenzii-u-patsientov-s-hronicheskoy-boleznyu-pochek-dodializnoy-stadii-po-dannym-ehokardiografii
https://cyberleninka.ru/article/n/otsenka-legochnoy-gipertenzii-u-patsientov-s-hronicheskoy-boleznyu-pochek-dodializnoy-stadii-po-dannym-ehokardiografii.pdf -
10Academic Journal
Θεματικοί όροι: программный гемодиализ, реципиенты почечного трансплантата, гипертрофия миокарда левого желудочка, хроническая болезнь почек, left ventricular myocardial hypertrophy, kidney transplant recipients, chronic kidney disease, program hemodialysis, 3. Good health
Σύνδεσμος πρόσβασης: https://magazine.lvrach.ru/jour/article/view/79/0
-
11Academic Journal
Συγγραφείς: V. N. Poptsov, E. A. Spirina, I. V. Pashkov, A. V. Belikova, D. O. Oleshkevich, R. A. Latipov, O. M. Tsirulnikova, A. C. Epremian, E. F. Shigaev, S. V. Gautier, В. Н. Попцов, Е. А. Спирина, И. В. Пашков, А. В. Беликова, Д. О. Олешкевич, Р. А. Латыпов, О. М. Цирульникова, А. С. Епремян, Е. Ф. Шигаев, С. В. Готье
Πηγή: Russian Journal of Transplantology and Artificial Organs; Том 20, № 4 (2018); 30-37 ; Вестник трансплантологии и искусственных органов; Том 20, № 4 (2018); 30-37 ; 1995-1191 ; 10.15825/1995-1191-2018-4
Περιγραφή αρχείου: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/947/751; Corris P, Degano B. Severe pulmonary arterial hypertension treatment option sand the bridge to transplantation. Eur Respir Rev. 2014; 23: 488–497.; McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015; 65: 1976–1997.; Sultan S, Tseng S, Stanziola AA et al. Pulmonary Hypertension: The Role of Lung Transplantation. Heart Fail Cin. 2018; 14: 327–331.; Machuca TN, Collaud S, Mercier O et al. Outcomes of intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation. J Thorac Cardiovasc Surg. 2015; 149: 1152–1157.; Merlo CA, Weiss ES, Orens JB et al. Impact of U. S. Lung Allocation Score on survival after lung transplantation. J Heart Lung Transplant. 2009; 28: 769–775.; Orens JB, Boehler A, de Perrot M et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003; 22: 1183–2000.; Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Respir J. 1995; 8: 492–506.; Van Raemdonck D, Neyrinck A, Verleden GM et al. Lung donor selection and management. Proc Am Thorac Soc. 2009; 6: 28–38.; Oto T, Levvey BJ, Snell G. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant. 2007; 26: 431–436.; McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006; 114: 1417–1431.; Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122: 156–163.; Kamler M, Pizanis N, Aleksic I et al. Pulmonary hypertension and lung transplantation. Herz. 2005; 30: 281– 285.; McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477–1482.; Christie JD, Edwards LB, Autora P et al. The registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart-lung transplantation report. J Heart Lung Transplant. 2009; 28: 1031–1049.; Katz WE, Gasior TA, Quinlan JJ et al. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension. J Am Coll Cardiol. 1996; 27: 384– 391.; Birsan T, Zuckermann Z, Artermiou O et al. Bilateral lung transplantation for pulmonary hypertension. Transplant Proc. 1997; 29: 2892–2894.; Julliard WA, Meyer KC, De Oliveira NC et al. The presence or severity of pulmonary hypertension does not affect for single-lung transplantation. Thorax. 2016; 71: 478–480.; Yusen RD, Edwards LB, Kucheryavaya AY et al. The registry of International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report – 2015. J Heart Lung Transplant. 2015; 34: 1264–1277.; Hill C, Maxwell B, Boulate D et al. Heart-lung vsdouble-lung transplantation for idiopathic pulmonary arterial hypertension. Clin Transplant. 2015; 29: 1067–1075.; Fang A, Studer S, Kawut SM et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest. 2011; 139: 782–787.; Wisser W, Marta G, Senbaklavica O et al. BLTX with intra- and postoperatively prolonged ECMO in patients with pulmonary hypertension: beneficial effect on initial organ function. J Heart Lung Transplant. 2001; 20: 224–225.; Pereszlenyi A, Lang G, Steltzer H et al. Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension. Eur J Cardiothorac Surg. 2002; 21: 858–863.; Mozer B, Jaksch P, Taghavi S et al. Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome. Eur J Cardiothorac Surg. 2018; 53: 178–185.; https://journal.transpl.ru/vtio/article/view/947
-
12Academic Journal
Συγγραφείς: V. N. Poptsov, E. A. Spirina, S. Yu. Ustin, S. A. Masutin, A. A. Dogonacheva, V. Yu. Voronkov, E. N. Zolotova, A. I. Skokova, В. Н. Попцов, Е. А. Спирина, С. Ю. Устин, С. А. Масютин, А. А. Догнашева, В. Ю. Воронков, Е. Н. Золотова, А. И. Скокова
Πηγή: Russian Journal of Transplantology and Artificial Organs; Том 21, № 1 (2019); 7-16 ; Вестник трансплантологии и искусственных органов; Том 21, № 1 (2019); 7-16 ; 1995-1191 ; 10.15825/1995-1191-2019-1
Θεματικοί όροι: гипертрофия миокарда левого желудочка, left ventricular hypertrophy
Περιγραφή αρχείου: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/984/772; Laks H, Marelli D, Fonarow GC et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg. 2003; 125: 49–59.; Patel J, Kobashigawa JA.Cardiac transplantation: the alternate list and expansion of the donor pool. Curr Opin Cardiol. 2004; 19: 162–165.; Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997; 10 (6): 446–450.; Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008; 51 (12): 1214–1220.; Шумаков ВИ. Трансплантация сердца: Руководство для врачей. Под ред. В.И. Шумакова. М.: Медицинское информационное агентство, 2006: 400.; Costanzo MR, Dipchand A, Starling R et al. The International Society of Heart and Lung Transplanation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29: 914–956.; Jahania MS, Mullett TW, Sanchez JA et al. Acute allograft failure in thoracic organ transplantation. J Card Surg. 2000; 15: 122–128.; Wernovsky G, Wypij D, Jonas RA et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of lowflow cardiopulmonary bypass and circulatory arrest. Circulation. 1995; 92: 2226–2235.; Gao SZ, Alderman EL, Schroeder JS, Hunt SA.Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic finding. J Am Coll Cardiol. 1988; 12: 334–340.; Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005; 24 (11): 1710–1720.; Berry GJ, Burke MM, Andersen C et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013; 32 (12): 1147–1162.; Lima B, Rajagopal K, Petersen RP et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation. 2006 Jul 4; 114 (1 Suppl): I27–32.; Taylor DO, Stenhlik J, Edwards LB.Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplantation Report – 2009. J Heart Lung Transplant. 2009; 28: 1007– 1022.; Marelli D, Laks H, Fazio D et al. The use donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000; 19: 496–503.; The International Society of Heart and Lung Transplantation. Guidelines for the care of heart transplant recipients. Task Force 1: Peri-operative Care of the Heart Recipients. Use of Donors with Pre-existing Cardiac Abnormalities. J Heart Lung Transplant. 2010; 29: 914– 956.; Bernhardt AM, Reichenspurner H.High-risk donors: extending our criteria in times of organ shortage. Curr Opin Organ Transplant. 2014; 19: 494–499.; Abid Q, Parry G, Forty J et al. Concurrent coronary grafting of the donor heart with left internal mammary artery: 10-year experience. J Heart Lung Transplant. 2002; 21: 812–814.; Rabago G, Martin-Trenor A, Lopez Coronaro JL et al. Coronary angioplasty and stenting following heart transplantation with older donor: Is this a rational approach? Eur J Cardiothorac Surg. 1998; 13: 209–211.; Chen JM, Russo MJ, Hammond KM et al. Alternative waiting list strategies for heart transplantation minimize organ donor utilization. Ann Thorac Surg. 2005; 80: 224–228.; Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant. 2007; 7 (10): 2388–2395.; Grant SC, Rahman AN, Brooks NH.Regression of left ventricular hypertrophy in a transplanted heart. Br Heart J. 1992; 68 (1): 55–57.; https://journal.transpl.ru/vtio/article/view/984
-
13Academic Journal
Συγγραφείς: A. Kochetkov I., E. Borisova V., O. Ostroumova D., M. Lopukhina V., G. Piksina V., А. Кочетков И., Е. Борисова В., О. Остроумова Д., М. Лопухина В., Г. Пиксина Ф.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 15, No 3 (2019); 305-314 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 3 (2019); 305-314 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2019-15-3
Θεματικοί όροι: arterial hypertension, middle age, left ventricular hypertrophy, stiffness, strain, speckle tracking, antihypertensive therapy, single-pill combinations of antihypertensive drugs, amlodipine, valsartan, артериальная гипертония, средний возраст, гипертрофия миокарда левого желудочка, жесткость, стрейн, антигипертензивная терапия, фиксированные комбинации антигипертензивных препаратов, амлодипин, валсартан
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1950/1819; Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.; Kannel W.B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13(Suppl D):82-8. DOI:10.1093/eurheartj/13.suppl_D.82.; Stevens S.M., Reinier K., Chugh S.S. Increased left ventricular mass as a predictor of sudden cardiac death: is it time to put it to the test? Circulation: Arrhythmia and Electrophysiology. 2013;6(1):212-7. DOI:10.1161/CIRCEP.112.974931.; Bombelli M., Facchetti R., Carugo S., et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27(12):2458-64. DOI:10.1097/HJH.0b013e328330b845.; Bouzas-Mosquera A., Broullo´n F.J., A´ lvarez-Garcı´a N., et al. Association of Left Ventricular Mass with All-Cause Mortality, Myocardial Infarction and Stroke. PLoS ONE. 2012;7(9):e45570. DOI:10.1371/journal.pone.0045570.; de Simone G., Gottdiener J.S., Chinali M., et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: The Cardiovascular Health Study. Eur Heart J. 2008;29(6):741-7. DOI:10.1093/eurheartj/ehm605.; Chrispin J., Jain A., Soliman E.Z., et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(19):2007-13. DOI:10.1016/j.jacc.2014.01.066.; Paoletti E., De Nicola L., Gabbai F.B., et al. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension. Clin J Am Soc Nephrol. ;11(2):271-9. DOI:10.2215/CJN.06980615.; Shi H.T., Wang X.J., Li J., et al. Association of Left Ventricular Hypertrophy with a Faster Rate of Renal Function Decline in Elderly Patients with Non‐End‐Stage Renal Disease. Journal of the American Heart Association. 2015;4(11):e002213. DOI:10.1161/JAHA.115.002213.; Santos M., Shah A.M. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep. 2014;16(5):428. DOI:10.1007/s11906-014-0428-x.; Gosse P. Left ventricular hypertrophy-the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A-11A. DOI:10.1177/14732300050330S102.; Musini V.M., Gueyffier F., Puil L., et al. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev. 2017;8:CD008276. DOI:10.1002/14651858.CD008276.pub2.; O’Brien E., Parati G., Stergiou G., et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Guidelines European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension. 2013;31:1731-68. DOI:10.1097/HJH.0b013e328363e964.; Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.; Marwick T.H., Gillebert T.C., Aurigemma G., et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015;16(6):577-605. DOI:10.1093/ehjci/jev076.; Mor-Avi V., Lang R.M., Badano L.P., et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24(3):277-313. DOI:10.1016/j.echo.2011.01.015.; Shang Q., Tam L.S., Sanderson J.E., et al. Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford). 2012;51(12):2215-23. DOI:10.1093/rheumatology/kes213.; Borlaug B.A., Redfield M.M., Melenovsky V., et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail. 2013;6(5):944-52. DOI:10.1161/CIRCHEARTFAILURE.113.000383.; Остроумова О.Д., Борисова Е.В., Кочетков А.И., и др. Улучшение когнитивных функций пациентов среднего возраста с эссенциальной артериальной гипертензией в результате лечения фиксированной комбинацией амлодипин/валсартан. Рациональная Фармакотерапия в Кардиологии. 2019;15(1):54-62. DOI:10.20996/1819-6446-2019-15-1-54-62.; Kang S.J., Lim H.S., Choi B.J., et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr. 2008;21(8):907-11. DOI:10.1016/j.echo.2008.01.015.; Krämer J., Niemann M., Liu D., et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013;34(21):1587-96. DOI:10.1093/eurheartj/eht098.; Ishizu T., Seo Y., Kameda Y., et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014;63(3):500-6. DOI:10.1161/HYPERTENSIONAHA.113.02149.; Kucukler N., Kurt I.H., Topaloglu C., et al. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Med (Hagerstown). 2012;13(3):181-6. DOI:10.2459/JCM.0b013e3283511f00.; Suzuki K., Kato K., Soda S., et al. The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients. Diabetes Obes Metab. 2004;6(3):195-9. DOI:10.1111/j.1462-8902.2004.00331.x.; Zhi-Bin H., Chang F., Mao-Huan L., et al. Valsartan improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Hypertens Res. 2014;37(9):824-9. DOI:10.1038/hr.2014.85.; Deng X.U., Xia K.E., Chen P.O., et al. Reversion of left ventricle remodeling in spontaneously hypertensive rats by valsartan is associated with the inhibition of caspase-3, -8 and -9 activities. Biomed Rep. 2015;3(4):533-6. DOI:10.3892/br.2015.458.; Li W., Sun N., Liu W., et al. Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats. Chin Med J (Engl). 2002;115(3):364-6.; Correia-Pinto J., Henriques-Coelho T., Roncon-Albuquerque R. Jr., et al. Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension. Basic Res Cardiol. 2009;104(5):535-45. DOI:10.1007/s00395-009-0017-3.; Zhang X., Li Z.L., Crane J.A., et al. Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension. Hypertension. 2014;64(1):87-93. DOI:10.1161/HYPERTENSIONAHA.113.02151.; Агеев Ф.Т., Овчинников А.Г., Сербул В.М., Беленков Ю.Н. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная Терапия и Профилактика. 2008;7(2):98-108.; Hunter J.J., Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341(17):1276-83. DOI:10.1056/NEJM199910213411706.; Абатурова О.В., Кремнева Л.В., Шалаев С.В. Гипертрофия миокарда левого желудочка: роль гемодинамических и нейрогормональных факторов, молекулярно-клеточные механизмы развития. Уральский Медицинский Журнал. 2004;7:11-6.; Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. Journal of Hypertension. 2012;30(4):685-7. DOI:10.1097/HJH.0b013e328350e5db.; Jellis C., Martin J., Narula J., Marwick T.H. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89-97. DOI:10.1016/j.jacc.2010.02.047.; Imbalzano E., Zito C., Carerj S., et al. Left ventricular function in hypertension: new insight by speckle tracking echocardiography. Echocardiography. 2011;28(6):649-57. DOI:10.1111/j.1540-8175.2011.01410.x.; Mizuguchi Y., Oishi Y., Miyoshi H., et al. The functional role of longitudinal, circumferential, and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: a study with two-dimensional strain imaging. J Am Soc Echocardiogr. 2008;21:1138-44. DOI:10.1016/j.echo.2008.07.016.; Oishi Y., Miyoshi H., Iuchi A., et al. Negative impact of cardiovascular risk factors on left atrial and left ventricular function related to aortic stiffness-new application of 2-dimensional speckle-tracking echocardiography. Circ J. 2013;77:1490-8. DOI:10.1253/circj.CJ-12-1260.; Biering-Sørensen T., Biering-Sørensen S.R., Olsen F.J., et al. Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population: The Copenhagen City Heart Study. Circ Cardiovasc Imaging. 2017;10(3):e005521. DOI:10.1161/CIRCIMAGING.116.005521.; Nahum J., Bensaid A., Dussault C., et al. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging. 2010;3(3):249-56. DOI:10.1161/CIRCIMAGING.109.910893.; Bertini M., Ng A.C., Antoni M.L., et al. Global longitudinal strain predicts long-term survival in patients with chronic ischemic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(3):383-91. DOI:10.1161/CIRCIMAGING.111.970434.; Motoki H., Koyama J., Izawa A., et al. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography. 2014;31(10):1230-8. DOI:10.1111/echo.12548.; Carugo S., Bolla G. B., Famiani R., et al. Effects of valsartan treatment on indicators of cardiovascular damage in newly diagnosed hypertensive patients: A prospective, twelve-month, open-label, pilot study. Current Therapeutic Research. 2010;71(5):309-21. DOI:10.1016/j.curtheres.2010.10.002.; Xing S.S., Tan H.W., Bi X.P., et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. DOI:10.2119/2008-00024.Xing.; Siddesha J.M., Valente A.J., Sakamuri S.S., et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol. 2014;229(7):845-55. DOI:10.1002/jcp.24511.; Matsubara M., Hasegawa K. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol. 2004;498(1-3):303-14. DOI:10.1016/j.ejphar.2004.07.086.; Matsumori A., Nunokawa Y., Sasayama S. Nifedipine inhibits activation of transcription factor NFkappaB. Life Sci. 2000;67(21):2655-61. DOI:10.1016/S0024-3205(00)00849-3.; Iwasaki Y., Asai M., Yoshida M., et al. Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells. Clin Chim Acta. 2004;350(1-2):151-7. DOI:10.1016/j.cccn.2004.07.012.; https://www.rpcardio.com/jour/article/view/1950
-
14Academic Journal
Πηγή: В мире научных открытий, Vol 0, Iss 6, Pp 64-79 (2016)
Θεματικοί όροι: артериальная гипертензия, абдоминальное ожирение, цитокины, адипокины, дисфункция эндотелия, гипертрофия миокарда левого желудочка, толщина комплекса интима-медиа, Agriculture, Science
Περιγραφή αρχείου: electronic resource
Relation: http://journal-s.org/index.php/vmno/article/view/9143; https://doaj.org/toc/2072-0831; https://doaj.org/toc/2307-9428
Σύνδεσμος πρόσβασης: https://doaj.org/article/b9593c3314b54b57ae9b821c430d7d66
-
15Academic Journal
Συγγραφείς: O. Drapkina M., R. Shepel N., T. Deeva A., О. Драпкина М., Р. Шепель Н., Т. Деева А.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 1 (2018); 27-33 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 1 (2018); 27-33 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-1
Θεματικοί όροι: leptin, hypertrophy of the left ventricle, the metabolic syndrome, лептин, гипертрофия миокарда левого желудочка, метаболический синдром
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1613/1602; Drapkina O.M., Eliashevich S.O., Shepel R.N. Obesity is a risk factor for chronic noncommunicable diseases. Russian Journal of Cardiology. 2016;6:73-9. (In Russ.) [Драпкина О.М., Елиашевич С.О., Шепель Р.Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский Кардиологический Журнал. 2016;6:73-9]. doi:10.15829/1560-4071-2016-6.; Wong R.J., Chou C., Sinha S.R., et al. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437-45. doi:10.1007/s10900-0139792-8.; Saydah S., Bullard K.M., Cheng Y., et al. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010. Obesity (Silver Spring). 2014;22(8):1888-95. doi:10.1002/oby.20761.; Russian guidelines for management of patients with metabolic syndrome (2013). Available at: http://www.gipertonik.ru/files/recommendation/Recommendations_metabolic_syndrome.doc. Checked by 11/02/2018 (In Russ.) [Российские рекомендации по ведению больных с метаболическим синдромом (2013). Доступно на: http://www.gipertonik.ru/files/recommendation/Recommendations_metabolic_syndrome.doc. Проверено 11.02.2018].; Schillaci G., Verdecchia P., Porcellati C., et al. Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension. Hypertension. 2000;35:580-6. doi:10.1161/01.HYP.35.2.580.; Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronaryartery disease: a workshop consensus statement. Am Heart J. 1991;121:1244-63. doi:10.1016/00028703(91)90694-D.; Ametov A.S., Demidova T.Yu., Tselikovskaya A.L. Effect of leptin on the regulation of body weight. Serdechnaja Nedostatochnost'. 2001;2(3):309-11. (In Russ.) [Аметов А.С., Демидова Т.Ю., Целиковская А.Л. Влияние лептина на регуляцию массы тела. Сердечная Недостаточность. 2001; 2(3): 30911].; Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60: 349-356.; Chearskul S., Kooptiwut S., Pummoung S., et al. Obesity and appetite-related hormones. J Med Assoc Thai. 2012;95(11):1472-9.; Purdham D.M., Zou M.X., Rajapurohitam V., Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol. 2004;287:2877-84. doi:10.1152/ajpheart.00499.2004.; Rajapurohitam V., Gan X.T., Kirshenbaum L.A., Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res. 2003;93:277-9. doi:10.1161/01.RES.0000089255.37804.72.; Schulze P.C., Kratzsch J., Linke A., et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail. 2003;5:33-40. doi:10.1016/S13889842(02)00177-0.; Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens. 2006;23:789-801. doi:10.1097/01.hjh.0000222743.06584.66; Alberti K.G., Zimmet P., Shaw J. The Metabolic Syndrome A new worldwide definition from the International Diabetes Federation Consensus. Lancet. 2005; 366: 1059-62. doi:10.1111/j.14645491.2006.01858.x.; Vasyuk Yu.A., Sadulayeva IA, Yushchuk E.N. et al. Metabolic syndrome: new aspects of the old problem. Arterial'naja Gipertenzija. 2007; 13 (2): 34-6. (In Russ.) [Васюк Ю.А., Садулаева И.А., Ющук Е.Н. и др. Метаболический синдром: новые аспекты старой проблемы. Артериальная Гипертензия. 2007;13(2):34-6].; Drapkina O.M., Shepel R.N., Deeva T.A. Assessment of leptin level in patients with metabolic syndrome and coronary heart disease. Cardiovascular Therapy and Prevention. 2016;15(3):43-8. (In Russ.) [Драпкина О. М., Шепель Р. Н., Деева Т. А. Оценка уровня лептина у пациентов с метаболическим синдромом и ишемической болезнью сердца. Кардиоваскулярная Терапия и Профилактика. 2016;15(3):43-8]. doi:10.15829/1728-8800-2016-3-43-48.; Dagogo-Jack S., Fanelli C., Paramore D., et al. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes. 1996;45:695-8. doi:10.2337/diab.45.5.695.; Drapkina O.M., Deeva T.A., Popova I.R. Non-alcoholic fatty liver disease as an obligate sign of obesity. Rossijskie Medicinskie Vesti. 2012;17(4):4-10. (In Russ.) [Драпкина О.М., Деева Т.А., Попова И.Р. Неалкогольная жировая болезнь печени как облигатный признак ожирения. Российские Медицинские Вести. 2012;17(4):4-10].; Abe Y., Ono K., Kawamura T., et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol. 2007;292(5):238796. doi:10.1152/ajpheart.00579.2006; Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A. et al. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001; 104:3052-3056.; Chen M.S., Wang Y.Z., Yi Q, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110:1269-75. doi:10.1161/01.CIR.0000140766.52771.6D.; Correia M.L., Haynes W.G. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004;13(2):215-23.; https://www.rpcardio.com/jour/article/view/1613
-
16Academic Journal
Συγγραφείς: O. Ostroumova D., A. Kochetkov I., I. Kopchjonov I., V. Fomina M., О. Остроумова Д., А. Кочетков И., И. Копченов И., В. Фомина М.
Συνεισφορές: Гедеон Рихтер, компания
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 13, No 5 (2017); 693-698 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 5 (2017); 693-698 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-5
Θεματικοί όροι: arterial hypertension, obesity, ambulatory blood pressure monitoring, left ventricular hypertrophy, myocardial stiffness, артериальная гипертония, ожирение, суточное мониторирование артериального давления, гипертрофия миокарда левого желудочка, жесткость миокарда
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1546/1562; Boytsov S.A., Deev A.D., Shalnova S.A. Mortality and risk factors for non-communicable diseases in Russia: Specific features, trends, and prognosis. Terapevticheskiy Arkhiv. 2017;89(1):5-13. (In Russ.) [Бойцов С.А., Деев А.Д., Шальнова С.А. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический Архив. 2017;89(1):5-13]. doi:10.17116/terarkh20178915-13.; Samorodskaja I.V., Bolotova E.Y., Boytsov S.A. Paradox of obesity and cardiovascular mortality. Kardiologiia. 2015;55(9):31-6. (In Russ.) [Самородская И.В., Болотова Е.В., Бойцов С.А. Парадокс ожирения и сердечно-сосудистая смертность. Кардиология. 2015;55(9):31-6]. doi:10.18565/cardio.2015.9.31-36.; Zhang K., Huang F., Chen J., et al. Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis. Medicine. 2014;93(25):e130. doi:10.1097/MD.0000000000000130.; An H.J., Kim W., Kang C., et al. Other Korean Ambulatory Blood Pressure Registry Investigators. Obesity increases blood pressure variability during the night. J Korean Soc Hypertens. 2014;20(1):1-7.; Tadic M., Cuspidi C., Ilic I., et al. The relationship between blood pressure variability, obesity and left atrial phasic function in hypertensive population. The International Journal of Cardiovascular Imaging 2016;32(4):603-12. doi:10.1007/s10554-015-0822-8.; Ostroumova O.D., Kochetkov A.I., Lopukhina M.V. Comparative analysis of the efficacy of fixed-dose combinations of amlodipine/Lisinopril and bisoprolol/hydrochlorthiazide in patients with essential arterial hypertension combined with obesity and overweight. Rational Pharmacotherapy in Cardiology. 2017;13(4):457-67. (In Russ.) [Остроумова О.Д., Кочетков А.И., Лопухина М.В. Сравнительный анализ эффективности фиксированных комбинаций амлодипин/лизиноприл и бисопролол/гидрохлоротиазид у пациентов с гипертонической болезнью в сочетании с ожирением и избыточной массой тела. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):443-53. doi:10.20996/1819-6446-2017-13-4-443-453].; Tutal E., Sayın B., Ertugrul D.T., et al. Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients? International Journal of Nephrology and Renovascular Disease. 2013;6(1):71-7. doi:10.2147/IJNRD.S41384.; Lyzohub V.H., Dolynna O.V., Arutiunova K.Sh. Twenty four hour profile of arterial pressure in patients with hypertensive disease and concurrent obesity. Lik Sprava. 2002;(8):39-42.; Hassan M.O., Jaju D., Albarwani S., et al. Non-dipping blood pressure in the metabolic syndrome among Arabs of the Oman family study. Obesity (Silver Spring). 2007;15(10):2445-53. doi:10.1038/oby.2007.290.; Verdecchia P., Angeli F., Gattobigio R., et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. American Journal of Hypertension. 2007;20(2):154-61. doi:10.1016/j.amjhyper.2006.07.017.; Willich S.N. Circadian variation and triggering of cardiovascular events. Vascular Medicine. 1999;4(1):41-49. doi:10.1177/1358836X9900400108.; Fagard R.H., Thijs L., Staessen J. A., et al. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. Journal of Human Hypertension. 2009;23(10):645-53. doi:10.1038/jhh.2009.9.; Ohkubo T., Hozawa A., Yamaguchi J., et al. Prognostic significance of the nocturnal decline in blood pressure: the Ohasama study. Journal of Hypertension. 2002;20:2183-9. doi:10.1097/00004872-200211000-00017.; Kario K., Pickering T.G., Matsuo T., et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38(4):852-7. doi:10.1161/hy1001.092640.; Guo H., Tabara Y., Igase M., et al. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J-SHIPP study. Hypertens Res. 2010;33(1):32-6. doi:10.1038/hr.2009.; Cuspidi C., Macca G., Sampieri L., et al. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens. 2001;19:1539-45.; Cuspidi C., Michev I., Meani S., et al. Reduced nocturnal fall in blood pressure, assessed by two ambulatory blood pressure monitorings and cardiac alterations in early phases of untreated essential hypertension. Journal of Human Hypertension. 2003;17:245-51. doi:10.1038/sj.jhh.1001546.; Pierdomenico S., Bucci A., Costantini F., et al. Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol. 1998;31(7):1627-34. doi:10.1016/S0735-1097(98)00163-6.; Timio M., Venanzi S., Lolli S., et al. "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clinical Nephrology. 1995;43(6):382-7.; Cheng S., Xanthakis V., Sullivan L.M., et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation. 2010;122(6):570-8. doi:10.1161/CIRCULATIONAHA.110.937821.; Marwick T.H., Gillebert T.C., Aurigemma G., et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015;16(6):577-605. doi:10.1093/ehjci/jev076.; Sun T., Xie J., Zhu L., et al. Left ventricular hypertrophy and asymptomatic cardiac function impairment in chinese patients with simple obesity using echocardiography. Obesity Facts. 2015;8(3):210-9. doi:10.1159/000435795.; Unsöld B., Bremen E., Didié M., et al. Differential PI3K signal transduction in obesity‑associated cardiac hypertrophy and response to ischemia. Obesity. 2015;23(1):90-9. doi:10.1002/oby.20888.; Kannel W.B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992;13(Suppl D):82-8. doi:10.1093/eurheartj/13.suppl_D.82.; Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proceedings of the National Academy of Sciences. 2000;97(4):1784-9.; Brady T.M. The Role of Obesity in the Development of Left Ventricular Hypertrophy Among Children and Adolescents. Curr Hypertens Rep. 2016;18(1):3. doi:10.1007/s11906-015-0608-3.; Mangner N., Scheuermann K., Winzer E., et al. Childhood obesity: impact on cardiac geometry and function. JACC: Cardiovascular Imaging. 2014;7(12):1198-205. doi:10.1016/j.jcmg.2014.08.006.; Kang S.J., Lim H.S., Choi B.J., et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr. 2008;21:907-11. doi:10.1016/j.echo.2008.01.015.; Biering-Sørensen T., Biering-Sørensen S. R., Olsen F. J., et al. Global Longitudinal Strain by Echocardiography Predicts Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population. Circulation: Cardiovascular Imaging. 2017;10(3):e005521. doi:10.1161/CIRCIMAGING.116.005521.; Ishizu T., Seo Y., Kameda Y., et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014; 63(3):500-6. doi:10.1161/HYPERTENSIONAHA.113.02149.; Crendal E., Walther G., Vinet A., et al. Myocardial deformation and twist mechanics in adults with metabolic syndrome: impact of cumulative metabolic burden. Obesity. 2013;21(12):E679-E686. doi:10.1002/oby.20537.; Krishnasamy R., Hawley C. M., Stanton T., et al. Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. BMC Nephrology. 2015;16(1):106. doi:10.1186/s12882-015-0098-1.; Вetin M., Kocaman S.A., Durakoğlugil M.E., et al. Effect of epicardial adipose tissue on diastolic functions and left atrial dimension in untreated hypertensive patients with normal systolic function. J Cardiol. 2013;61:359-64. doi:10.1016/j.jjcc.2012.12.015.; Gonçalves N., Silva A.F., Rodrigues P.G., et al. Early cardiac changes induced by a hypercaloric Western-type diet in “subclinical” obesity. American Journal of Physiology-Heart and Circulatory Physiology. 2016;310(6):H655-H666. doi:10.1152/ajpheart.00684.2015.; Mahfouz R. A., Gomma A., Goda M., Safwat M. Relation of left atrial stiffness to insulin resistance in obese children: Doppler strain imaging study. Echocardiography. 2015;32(7):1157-63. doi:10.1111/echo.12824.; https://www.rpcardio.com/jour/article/view/1546
-
17Academic Journal
Συγγραφείς: O. Ostroumova D., A. Kochetkov I., I. Kopchjonov I., V. Fomina M., О. Остроумова Д., А. Кочетков И., И. Копченов И., В. Фомина М.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 13, No 6 (2017); 841-850 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 6 (2017); 841-850 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-6
Θεματικοί όροι: arterial hypertension, obesity, ambulatory blood pressure monitoring, left ventricular hypertrophy, myocardial stiffness, fixed-dose combinations of antihypertensive drugs, amlodipine, lisinopril, артериальная гипертония, ожирение, суточное мониторирование артериального давления, гипертрофия миокарда левого желудочка, жесткость миокарда, фиксированные комбинации антигипертензивных препаратов, амлодипин, лизиноприл
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1577/1579; Boytsov S.A., Deev A.D., Shalnova S.A. Mortality and risk factors for non-communicable diseases in Russia: Specific features, trends, and prognosis. Ter Arkhiv. 2017;89(1):5-13. (In Russ.) [Бойцов С.А., Деев А.Д., Шальнова С.А. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический Архив. 2017;89(1):5-13]. doi:10.17116/terarkh20178915-13.; Samorodskaja I.V., Bolotova E.Y., Boytsov S.A. Paradox of obesity and cardiovascular mortality. Kardiologiia. 2015;55(9):31-6. (In Russ.) [Самородская И.В., Болотова Е.В., Бойцов С.А. Парадокс ожирения и сердечно-сосудистая смертность. Кардиология. 2015;55(9):31-6]. doi:10.18565/cardio.2015.9.31-36.; Chazova I.E., Ratova L.G., Boitsov S.A., Nebieridze D.V. Guidelines for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Sistemnye Gipertenzii. 2010;3:5-26. (In Russ.) [Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010;3:5-26].; Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281357. doi:10.1097/01.hjh.0000431740.32696.cc.; Jamerson K., Weber M. A., Bakris G. L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182.; Donskaja A.A., Morozov S.N., Morozova E.A. Evaluation of the effect of monotherapy with the Equator on hemodynamic parameters in persons with arterial hypertension. Cardiovascular Therapy and Prevention. 2008;6(4) Suppl 2:37. (In Russ.) [ДонскаяА.А. Морозов С.Н., Морозова Е.А. Оценка влияния монотерапии Экватором на гемодинамические показатели у лиц с артериальной гипертонией. Кардиоваскулярная Терапия и Профилактика. 2008;6(4) Приложение 2:37].; Ersh I.R. Zaicev V.I., Romanchuk E.V., et al. Efficacy of long-term therapy with the Equator in patients with arterial hypertension in ambulatory conditions. Mezhdunarodnye Obzory: Klinicheskaya Praktika i Zdorov’e. 2014;2(8):74-86. (In Russ.) (Ерш И.Р., Зайцев В.И., Романчук Э.В., и др. Эффективность длительной терапии препаратом Экватор больных артериальной гипертензией в амбулаторных условиях. Международные Обзоры: Клиническая Практика и Здоровье. 2014;2(8):74-86].; Kozhyrenko A.V. Clinical and epidemiological characteristics of arterial hypertension in young and middle-aged men in organized groups. The author's abstract of the dissertation of the candidate of medical sciences 2009. (In Russ.) (Козыренко А. В. Клинико-эпидемиологическая характеристика артериальной гипертонии у мужчин молодого и среднего возраста в организованных коллективах. Автореф. дисс. канд. мед. наук 2009).; Ostroumova O.D., Kochetkov A.I., Lopukhina M.V. Comparative analysis of the efficacy of fixed-dose combinations of amlodipine/Lisinopril and bisoprolol/hydrochlorthiazide in patients with essential arterial hypertension combined with obesity and overweight. Rational Pharmacotherapy in Cardiology. 2017;13(4):457-67. (In Russ.) [Остроумова О.Д., Кочетков А.И., Лопухина М.В. Сравнительный анализ эффективности фиксированных комбинаций амлодипин/лизиноприл и бисопролол/гидрохлоротиазид у пациентов с гипертонической болезнью в сочетании с ожирением и избыточной массой тела. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):443-53.] doi:10.20996/1819-6446-2017-13-4-443-453.; Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., et al. Comparative effectiveness of fixed-dose combinations of lisinopril/amlodipine and enalapril/hydrochlorothiazide. Cardiovascular Therapy and Prevention. 2013;12(2):25-29. (In Russ.) [Недогода С. В., Чумачек Е. В., Ледяева А. А., и др. Сравнительная эффективность фиксированных комбинаций лизиноприла с амлодипином и эналаприла с гидрохлортиазидом. Кардиоваскулярная Терапия и Профилактика. 2013;12(2):25-9]. doi:10.15829/1728-8800-2013-2-25-29.; Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med. 1986;15:254-73. doi:10.1016/0091-7435(86)90045-9.; Kannel W. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hyper. 2000;13(Pt. 2):S3−S10. doi:10.1016/S0895-7061(99)00252-6.; Dahlöf B., Sever P.S., Poulter N.R., et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. doi:10.1016/S01406736(05)67185-1.; Williams B., Lacy P.S., Thom S.M., et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213-25. doi:10.1161/CIRCULATIONAHA.105.595496.; Domanski M.J., Davis B.R., Pfeffer M.A., et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension. 1999;34:375-380. doi:10.1161/01.HYP.34.3.375.; Fernández-Escribano HernЗndez M., SuЗrez FernЗndez C., SЗez Vaquero T., et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp. 2007;207(6):284-290. doi:10.1157/13106850.; Nair G.V., Chaput L.A., Vittinghoff E., Herrington D.M. Heart and Estrogen/Progestin Replacement Study Investigators. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest. 2005;127(5):1498-506. doi:10.1378/chest.127.5.1498.; Peters R., Beckett N., Fagard R., et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial HYVET. J Hypertens. 2013;31(9):1868-75. doi:10.1097/HJH.0b013e3283622cc6.; Benetos A., Safar M., Rudnichi A., et l. Pulse pressure. Hypertension. 1997:30(6);1410-1415. doi:10.1161/01.HYP.30.6.1410.; Dolan E., Stanton A.V., Thom S., et al.; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27(4):876-885. doi:10.1097/HJH.0b013e328322cd62.; Dolan E., Stanton A., Thijs L., et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-61. doi:10.1161/01.HYP.0000170138.56903.7a.; Fagard R. H., Thijs L., Staessen J. A., et al. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):64553. doi:10.1038/jhh.2009.9.; Kario K., Pickering T.G., Matsuo T., et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38(4):852-7. doi:10.1161/hy1001.092640.; London G., Schmieder R., Calvo C., Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. American Journal of Hypertension. 2006;19(1):113-21. doi:10.1016/j.amjhyper.2005.06.027.; Mancia G., Parati G., Bilo G., et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25:1087-94. doi:10.1097/HJH.0b013e32805bf8ce.; Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens. 2006;20:787-94. doi:10.1038/sj.jhh.1002067.; Verdecchia P., Angeli F., Gattobigio R., et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. American Journal of Hypertension. 2007;20(2):15461. doi:10.1016/j.amjhyper.2006.07.017.; Kario K., Pickering T.G., Umeda Y., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation. 2003;107:1401-6. doi:10.1161/01.CIR.0000056521.67546.AA.; Schillaci G., Verdecchia P., Porcellati C., et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertens. 2000;35:580-6. doi:10.1161/01.HYP.35.2.580.; Nakili B., Okin P., Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-41. doi:10.1067/mhj.2001.113218.; Schirmer H., Lunde P., Rasmussen K. Prevalence of left ventricular hypertrophy in a general population. The Tromso Study. Eur Heart J. 1999;20:429-38. doi:10.1053/euhj.1998.1314.; Bakaev R., Strutynskij A., Glazunov A., et al. Equator in patients with hypertension, combined with coronary heart disease and chronic heart failure. Vrach. 2010;2:44-7. (In Russ.) [Бакаев Р., Струтынский А., Глазунов А., Каракин А., Воронина М., Пехтерева Д. Экватор у больных с гипертонической болезнью, сочетающейся с ишемической болезнью сердца и хронической сердечной недостаточностью. Врач. 2010;2:44-7].; Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9.; Soroka N.F., Bel'skaya E.S. Equator fixed-dose combination of amlodipine and lisinopril in the treatment of patients with arterial hypertension. Zdravookhranenie. 2007;7:17-21. (In Russ.) [Сорока Н.Ф., Бельская Е.С. Экватор фиксированная комбинация лизиноприла и амлодипина в лечении больных артериальной гипертензией. Здравоохранение. 2007;7:17-21].; Prokof'eva E.B., Glezer M.G. The stiffness of the arterial wall and the central hemodynamics with prolonged combined antihypertensive therapy. Kardiologiia. 2015;4(55):19-24. (In Russ.) [Прокофьева Е.Б., Глезер М.Г. Жесткость артериальной стенки и показатели центральной гемодинамики на фоне длительной комбинированной антигипертензивной терапии. Кардиология. 2015;4(55):19-24]. doi:10.18565/cardio.2015.4.19-24.; Morozov S.N., Donskaja A.A., Morozova E.A. The effectiveness of the equator treatment of patients with arterial hypertension (evidence from Yakutsk). Yakutskij Medicinskij Zhurnal. 2008;4(24):9-12. (In Russ.) [Морозов С.Н., Донская А.А., Морозова Е.А. Эффективность терапии экватором больных с артериальной гипертонией (на примере г. Якутска). Якутский Медицинский Журнал. 2008;4(24):9-12].; Kakhramanova S.M., Bahshaliev A.B. Antihypertensive and cardioprotective efficacy of the Equator in patients with essential hypertension. “Russian National Congress of Cardiologists. Improving the quality and availability of cardiac care (Congress materials)”. Cardiovascular Therapy and Prevention. 2008;7(6)b Suppl. 1:173. (In Russ.) [Кахраманова С.М., Бахшалиев А.Б. Антигипертензивная и кардиопротективная эффективность Экватора у больных эссенциальной гипертонией. «Российский национальный конгресс кардиологов. Повышение качества и доступности кардиологической помощи (материалы конгресса)». Кардиоваскулярная Терапия и Профилактика. 2008;7(6)б Приложение 1:173].; Ivanov K.M., Rybchinskaya I.I. Combined therapy of essential hypertension by drug Equator in patients with postsurgical hypothyroidism. Ural'skij Medicinskij Zhurnal. 2011;2:119-23. (In Russ.) [Иванов К.М., Рыбчинская И.И. Комбинированная терапия гипертонической болезни препаратом Экватор у больных с послеоперационным гипотиреозом. Уральский Медицинский Журнал. 2011;2:119-23].; Ageev F.T., Ovchinnikov A.G., Serbul V.M., Belenkov Ju.N. Left ventricle hypertrophy: the role of the renin-angiotensin system. Cardiovascular Therapy and Prevention. 2008;7(2):98-108. (In Russ.) [Агеев Ф.Т., Овчинников А.Г., Сербул В.М., Беленков Ю.Н. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная Терапия и Профилактика. 2008;7(2):98-108].; Krikunov P.V., Vasjuk Ju.A., Kopeleva M.V., Krikunova O.V. Left ventricle hypertrophy as a target for therapeutic intervention. Diagnostic and treatment aspects. Serdce. 2008;6(7):324-34. (In Russ.) (Крикунов П.В., Васюк Ю.А., Копелева М.В., Крикунова О.В. Гипертрофия левого желудочка как мишень для терапевтического вмешательства. Особенности диагностики и лечения. Сердце. 2008;6(7):324-34].; Abaturova O.V., Kremneva L.V., Shalaev S.V. Hypertrophy of the left ventricle: the role of hemodynamic and neurohormonal factors, the molecular-cellular mechanisms of development. Ural'skij meditsinskij zhurnal. Meditsinskaja Nauka i Praktika. 2004;7:11-6. (In Russ.) [Абатурова О.В., Кремнева Л.В., Шалаев С.В. Гипертрофия миокарда левого желудочка: роль гемодинамических и нейрогормональных факторов, молекулярно-клеточные механизмы развития. Уральский медицинский журнал. Медицинская Наука и Практика. 2004;7:11-6].; Chudinovskih Ju.A., Eremeeva M.V., Suhacheva T.V., et al. The new data on the mechanisms of the effect of pharmacological treatment on myocardial hypertrophy in patients with obstructive form of hypertrophic cardiomyopathy. Klinicheskaya Fiziologiya Krovoobrashheniya. 2013;1:12-8. (In Russ.) [Чудиновских Ю.А., Еремеева М.В., Сухачева Т.В., и др. Новые данные о механизмах влияния фармакологического лечения на гипертрофию миокарда у пациентов с обструктивной формой гипертрофической кардиомиопатии. Клиническая Физиология Кровообращения. 2013;1:12-8].; Davies C.H., Harding S.E., Poole-Wilson P.A. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J. 1996;17(2):189-98. doi:10.1093/oxfordjournals.eurheartj.a014834.; Berglund T. Differential Regression of Electrocardiographic Left Ventricular Hypertrophy by Amlodipine Versus Atenolol in the ASCOT Trial. 18th Scientific Meeting of the European Society of Hypertension 2008;Abstract PS17. J Hypertens. 2008;26(suppl 1):S254. Abstract PS17/TUE/05.; Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. American Journal of Hypertension. 1992;5(2):95-110. doi:10.1093/ajh/5.2.95.; Schmieder R.E., Schlaich M.P., Klingbeil A.U., Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998 Mar;13(3):564-9. doi:10.1093/ndt/13.3.564.; Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment. Hypertension. 2009;54(5):1084-91. doi:10.1161/HYPERTENSIONAHA.109.136655.; Leonova M.V. Modern Approaches to Treat Arterial Hypertension with beta-Blockers. Lechebnoe Delo. 2012;2:14-20. (In Russ.) [Леонова М. В. Современные аспекты применения бета-блокаторов в лечении артериальной гипертонии. Лечебное Дело. 2012;2:14-20].; Diez J., Lopez B., Gonzales A., Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 2001;16:328-335. doi:10.1097/00001573-200111000-00003.; Weber K.T., Brilla C.G., Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-8. doi:10.1093/cvr/27.3.341.; Diez M. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens. 2007;9:546-50. doi:10.1111/j.1524-6175.2007.06626.x.; Borlaug B.A., Lam C.S., Roger V.L., et al. Contractility and ventricular systolic stiffening in hypertensive heart disease. Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-8. doi:10.1016/j.jacc.2009.05.013.; Tsai W.C., Huang Y.Y., Liu Y.W., et al. Changes of left atrial phasic function assessed by speckle tracking echocardiography in untreated hypertension. Journal of Medical Ultrasound 2012;20:220-7. doi:10.1016/j.jmu.2012.10.010.; Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi:10.1016/j.echo.2014.10.003.; Tsang T.S., Barnes M.E., Abhayaratna W.P., et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol. 2006;97:916-20. doi:10.1016/j.amjcard.2005.09.143.; Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-93. doi:10.1161/01.CIR.102.12.1388.; Diez J., Laviades C., Mayor G., et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-6. doi:10.1161/01.CIR.91.5.1450.; Xing S.S., Tan H.W., Bi X.P., et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. doi:10.2119/2008-00024.Xing.; Siddesha J.M., Valente A.J., Sakamuri S.S., et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol. 2014;229(7):845-55. doi:10.1002/jcp.24511; https://www.rpcardio.com/jour/article/view/1577
-
18Academic Journal
Συγγραφείς: Н. Ф. Яковлева, А. В. Яковлев, С. В. Пономарёв, А. К. Снегирькова, И. М. Феликов, Е. А. Баймаева
Πηγή: Патология кровообращения и кардиохирургия, Vol 17, Iss 4, Pp 41-43 (2015)
Θεματικοί όροι: СИНДРОМ ОБСТРУКТИВНОГО АПНОЭ СНА, АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ, ОЖИРЕНИЕ, ПОСТОЯННОЕ ПОЛОЖИТЕЛЬНОЕ ДАВЛЕНИЕ В ВЕРХНИХ ДЫХАТЕЛЬНЫХ ПУТЯХ, ГИПЕРТРОФИЯ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА, ВАРИАБЕЛЬНОСТЬ СЕРДЕЧНОГО РИТМА, ЖЕЛУДОЧКОВЫЕ НАРУШЕНИЯ СЕРДЕЧНОГО РИТМА, Surgery, RD1-811
Περιγραφή αρχείου: electronic resource
Relation: http://journalmeshalkin.ru/index.php/heartjournal/article/view/95; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119
Σύνδεσμος πρόσβασης: https://doaj.org/article/46a6c66d0dcb40beb971697b2ca7c2ae
-
19Report
Θεματικοί όροι: arterial hypertension, алкоголь, сахарный диабет, прогнозирование, alcohol, артериальная гипертензия, left ventricular myocardial hypertrophy, острый коронарный синдром, 3. Good health, acute coronary syndrome, ретинопатия, гипертрофия миокарда левого желудочка, stress, predictors, age, diabetes mellitus, retinopathy, возраст, prognosis, предикторы, стресс
-
20Academic Journal
Συγγραφείς: Samarina, О., Kovtun, О., Самарина, О. В., Ковтун, О. П.
Θεματικοί όροι: PRIMARY HYPERTENSION, EARLY ONSET, CHILDREN, CARDIOVASCULAR RISK FACTORS, LEFT VENTRICULAR HYPERTROPHY, ЭССЕНЦИАЛЬНАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ, ДЕТИ, РАННИЙ ДЕБЮТ, ФАКТОРЫ РИСКА, ГИПЕРТРОФИЯ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА
Περιγραφή αρχείου: application/pdf
Relation: Уральский медицинский журнал. 2016. T. 139, № 6.; http://elib.usma.ru/handle/usma/13706
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/13706